Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

AKTUALNOŚCI >> Mabion and Vaxine Enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU

Mabion and Vaxine Enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU

On September 14, 2020 Mabion S.A. announced that the company has entered into a Memorandum of Understanding (MoU) with Vaxine Pty Ltd. (“Vaxine”), an Australian biotechnology company, outlining further agreements for the purpose of concluding a collaboration for the joint development, production and commercialization in the EU of Vaxine's vaccine candidate against SARS-CoV-2, which is currently being evaluated in a Phase I clinical study. Upon completion of the prospective cooperation agreements, Mabion will become Vaxine’s partner to further develop, manufacture and commercialize the vaccine in the European Union, including Poland.  

More information

© Mabion S.A. all rights reserved Polityka Prywatności